中国食品药品监管Issue(3)：4-17,14.DOI:10.3969/j.issn.1673-5390.2024.03.001
《中国医药产业高质量发展状况调研(2021-2023)》研究报告综述
Research Overview of the High-Quality Development Status of the Pharmaceutical Industry in China(2021-2023)
吴少祯 1严文君 1张燕玲 2方剑春 2马茗舒 2方佳璇 3茅宁莹 4李军 4陈秋佳4
作者信息
- 1. 中国健康传媒集团
- 2. 中国健康传媒集团健康中国研究院
- 3. 中国健康传媒集团大数据中心
- 4. 中国药科大学国际医药商学院
- 折叠
摘要
Abstract
Objective:To understand the transition and operational status of China's pharmaceutical industry towards high-quality development since the 14th Five-Year Plan,analyze the influence and role of regulatory policies in this transition,discuss the challenges faced by the industry,and put forward strategic suggestions for further advancement.Methods:Through literature research,surveys,interviews,and expert consultations to obtain relevant policy information,data,industry views,etc.Expert discussion are organized to support the research.Results:China's pharmaceutical industry has actively responded to the economic downward pressure,showing a resilience in industrial development,with significant advancements in new drug evaluation and listing,traditional Chinese medicine development,and regulatory science projects.Conclusion:The pharmaceutical industry in China is actively adjusting deeply towards high-quality development and transformation.At present,positive progress has been made in research and development innovation,manufacturing upgrading and innovation of traditional Chinese medicine.However,there are still challenges in research and development strategy,funding,traditional Chinese medicine inheritance and innovation,internationalization,and supply chain stability.It is recommended to further transform research and development strategies,diversify financing system,improve international supporting policies,reinforce traditional Chinese medicine supervision,deepen regulatory science,strengthen the construction of regulatory capacity,and promote the Tripartite Cooperation of Medical Services to effectively promote the high-quality development of the pharmaceutical industry.关键词
医药产业/高质量发展/创新/中药/药品制造/监管科学Key words
pharmaceutical industry/high-quality development/innovation/traditional Chinese medicine/drug manufacturing/regulatory science分类
医药卫生引用本文复制引用
吴少祯,严文君,张燕玲,方剑春,马茗舒,方佳璇,茅宁莹,李军,陈秋佳..《中国医药产业高质量发展状况调研(2021-2023)》研究报告综述[J].中国食品药品监管,2024,(3):4-17,14.
